Primary malignant giant cell tumor of the patella: report of a rare case

Achmad F. Kamal,1 Errol U. Hutagalung,2 Saukani Gumay,3 Yogi Prabowo,1 Yanuarso1

1 Department of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
2 Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
3 Department of Orthopaedic and Traumatology, Gatot Subroto Central Army Hospital, Jakarta, Indonesia

Abstract

Primary malignant giant cell tumor of the patella is a very rare case. It is a high-grade sarcoma characterized by a lesion in which there are areas of synchronous high-grade sarcomatous next to areas of benign GCT. A limb-sparing approach is applicable to virtually any bone lesion, whether low grade or high grade. We report a case with primary malignant GCT at the patella, from diagnostic to detailed limb-sparing surgery procedure. Fifteen months after surgery, the patient had a good functional outcome without local recurrence and distant metastasis.

Keywords: Limb-sparing surgery, primary malignant GCT, total patellectomy

Giant cell tumor (GCT) of bone was first described by Sir Astley Cooper in 1818. Historically, the lesion has been referred to by numerous terms, including myeloid sarcoma, tumor of myeloplaxus, osteoblastoclastoma, and osteoclastoma. GCT is a relatively common skeletal tumor, accounting for 4%-9.5% of all primary osseous neoplasms and 18%-23% of benign bone neoplasms. It is characterized by the presence of multinucleated giant cells. Of these, the majority of cases occur in the epiphysis of long bones.2,3

Malignant GCTs, whether representing primary or secondary changes from an originally benign tumor, are extremely rare. It is a high grade sarcoma arising in GCT as a primary or at the site of previously documented GCT (secondary). The incidence of malignant GCT is less than 0.5% of the total group of malignancy and 5.8% of all GCT. In Mayo Clinic, there were 35 malignant GCT documented from 11,087 tumor cases, and of these, there were only five cases of primary malignant GCT.4 There is a slight female predominance and patients are generally about a decade older than patients with GCT.5

We report a rare case of primary malignant GCT arising at the left patella focusing on diagnostic procedure and surgical management. This was the first case discovered and reported in Cipto Mangunkusumo Hospital, and probably in Indonesia. Some variation in surgical technique was performed to achieve treatment goal, which is to obtain functional union and avoid arthrodesis.

CASE PRESENTATION

A 31-year-old man presented to Orthopaedic Clinic Cipto Mangunkusumo Hospital, with chief complaint of ulcer on the lump at his left knee. Four years before admission, patient underwent trauma at the left knee and there was swelling. He went to bonesetter several times and had massages. The lump got worsen and it was getting bigger. Ten months before admission, the lump became bigger (15 x 12 x 10 cm), more painful, ulcerated, and produced sticky brown-yellowish and foul smelling exudate (Figure 1). Patient came to oncology division of surgery department, and had open biopsy with suspicion of malignant GCT. Patient then referred to orthopaedic oncology.

On physical examination, general condition was good and no abnormality was found in other organ. At the left knee, we found a big tumor at the patellar bone accompanied by necrotic tissue and a large ulcer at lower part of the tumor. No swelling or oedema on distal part of the tumor. The knee movement decreased with range of motion 0-60°.

The laboratory findings showed haemoglobin level 6.4 g/dL, white blood cells 8,100 cells/μL, an increase of erythrocyte sedimentation rate 40 mm/h (ref. < 20),
slightly increase of serum alkaline phosphatase 194 µ/L (ref. 35-187), and normal lactic dehydrogenase 97µ/L (ref. 100-190).

Radiographic examination of left knee anteroposterior and lateral projections showed expansile lytic lesion at the patella with well-defined margin and cortical thinning, multiple septation (soap bubble appearance), and destruction of the lower pool of patella (Figure 2).

Radiographic findings might suggest benign aggressive tumor (GCT or aneurysmal bone cyst) or malignancy, but was not enough to confirm whether it was malignant or not. Chest radiography and bone scintigraphy showed no evidence of metastasis on the lung and the other bones.

Patient underwent limb sparing surgery with total patellectomy and reconstruction of the extensor
mechanism using medial gastrocnemius muscle flap. The incision was designed from the proximal part of the mass in the distal femur and extended to shaft of the tibia. Wide excision with total patellectomy was done. Soft tissue attached to the tumor were sacrificed, thus it produced extensor mechanism defect. Then rotational flap was performed from medial gastrocnemius muscle to close the defect and to enhance the extensor mechanism. The distal incision was extended on the medial side of the leg to proximal ankle. After identifying medial gastrocnemius muscle, we detached that muscle from its aponeurosis and divided it from lateral part of gastrocnemius toward its proximal pedicle at the medial margin of sural nerve. After that, we rotated the muscle as a flap to close the defect and sutured it to the quadriceps.

Histopathological findings showed features of GCT with malignant component. Macroscopically, The resected tumor was yellowish, separated by bony tissue, and had central necrosis. Microscopic findings showed the characteristics of typical benign GCT, with ovoid-shaped tumor cells, mitosis, nuclear atypia, and multinucleated giant cells. Osteoid sarcomatous component was also found with its atypical, pleomorphic, bizarre cells, abnormal mitoses, and lacy pattern of osteoid (Figure 3). The margin of excision was free from the tumor.

After surgery, patient routinely came to the outpatient clinic. We performed evaluation by clinical and radiological examinations. Fifteen months after surgery, there was no local recurrence and distant metastasis. Patient had good functional outcome, he could walk and stand up without being assisted, ride a motorcycle, and work as a courier at an expedition company. There was improvement of knee motion, range of motion improved from 0-60° to 0-90°. According to Musculoskeletal Tumor Society scoring system (MSTS), functional outcome after surgery was 29 out of 30 (Figure 4).

DISCUSSION

GCT of the bone is a benign, locally aggressive neoplasm that is composed of sheets of neoplastic ovoid mononuclear cells interspersed with uniformly distributed large, osteoclast like giant cell. It represents around 4-5% of all bone tumors, and approximately 20% of all benign primary bone tumors. Although GCT affects all races, there is high prevalence in China and Southern India (State of Andhra Pradesh). The vast majority of GCTs affect skeletally mature patients, with approximately 80% occurring in patients between 20 and 50 years of age. The location of GCT is one of the most important features suggesting the diagnosis because approximately 84-99% of lesions extend within 1 cm of subarticular bone. The exact site of origin of GCT has been a controversy, commonly these lesions arise on the metaphyseal side of the epiphyseal plate. GCT usually occurs in the epiphysis of long bones, involving the lower end of the femur, the upper end of the tibia, and the lower end of the radius, in descending order. A small portion of GCT also occurs in patella, vertebrae, and skull.

Primary malignant GCT shows a slight female predominance, they are generally about a decade older than patients with GCT. Primary malignant GCT is histopathologically different from GCT. It is a lesion in which there are areas of synchronous high-grade malignant GCT. Figure 3. Photomicrographs of the primary malignant GCT. (A) Low magnification image showed mitosis, atypic, pleomorphic, and bizarre cells (white arrow). (B) Low magnification image showed atypic, pleomorphic, bizarre cells, and a lacy pattern of osteoid – representing sarcomatous component (black arrow) – and giant cells (asterisk). (Haematoxylin & eosin, x40)
Malignant giant cell tumor of patella

Figure 4. There was no local recurrence and range of movement of the knee was 0-90° at fifteen month follow-up

sarcomatous growth next to areas of benign GCT.\textsuperscript{3,5,9,10} It is very rare and considered as a representation of dedifferentiation in GCT,\textsuperscript{4} approximately 5 to 10% of GCT cases.\textsuperscript{2,10}

The patient had a growing lump at the patella since ten years before, without other organ disturbance. Slow tumor growth in this case conforms the benign tumor characteristics. Tumor growth acceleration was thought due to physical manipulation (massage) on the lump. Large ulcerated tumor with wide necrotic tissue depicted existent or probable character shift from benign to malignant lesion. Radiographic picture of expanding geographic lytic lesion with soap bubble appearance further confirmed the existence of aggressive benign tumor.\textsuperscript{1,11} From initial clinical and radiological examination, GCT or an aneurysmal bone cyst were the possible diagnoses. Since the available examinations were not adequate to work up the diagnosis, histopathological examination was then performed.

The histological diagnosis of malignant GCT is established only when the stromal cells are truly sarcomatous, as indicated by pleomorphism, atypical, and high mitotic activity. In addition, the areas of typical benign GCT should be in the tumor at the time of diagnosis, or in previous tissue taken from the same lesion. The histological features of the reported sarcomas include fibrosarcoma, osteosarcoma, malignant fibrous histiocytoma, and undifferentiated sarcoma.\textsuperscript{4,5,10}

In this patient, the resected tumor was yellowish, showed central necrosis, and separated by bony tissue. Microscopic findings revealed the presence of ovoid-shaped tumor cells, mitosis, and atypical nuclear with multinucleated giant cells as typical benign GCT components and also sarcomatous component. The sarcomatous component that we found was osteosarcoma. Because of no history of tumor reported at the same site, therefore this finding was consistent and highly suggestive with primary malignant GCT.

The role of chemotherapy is unclear in malignant GCT,\textsuperscript{6} so the choice of treatment for the tumor is a complete surgical excision.\textsuperscript{3,8-10} In this case, the tumor had been expanding out of patellar bone and involving the surrounding soft tissue, but it did not involve the femoral and tibial bones. The patient had wide excision with total patellectomy and then the defect on the extensor mechanism was reconstructed in order to enable him to walk. The lateral or medial gastrocnemius flap is useful for defects on the proximal third of the leg. We chose medial gastrocnemius flap because it is more easily done and have less complication than the lateral flap.\textsuperscript{12}

Reports on primary malignant GCT affecting other site such as distal femur or proximal tibia were found\textsuperscript{4,13} but no previous publication has ever reported primary malignant GCT of patella.

In conclusion, primary malignant GCT is an extremely rare case. By far, this is the first case of primary malignant giant cell tumor of patella.
malignant GCT that was found and reported in Cipto Mangunkusumo Hospital and probably in Indonesia. The diagnosis of primary malignant GCT was established based on histopathological findings such as sarcomatous component and the areas of typical benign GCT. Complete surgical excision and reconstruction with medial gastrocnemius flap is the treatment of choice of this primary malignant GCT at the patella.

REFERENCES


http://mji.ui.ac.id